PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Praxis Precision Medicines, Inc. on behalf of stockholders who may have suffered losses. The investigation focuses on potential violations of federal securities laws following Praxis's Q2 2025 financial results, which revealed adverse events in a study of its anti-seizure medication, leading to a 5.55% drop in stock price. Investors are encouraged to contact the firm for legal options.
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments